Verseon Corporation Verseon presents HAE program at Biotech Showcase
10 January 2018 - 6:00PM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
10 January 2018
Press release January 10, 2018
Verseon Corporation
("Verseon" or the "Company")
Verseon presents hereditary angioedema program at Biotech
Showcase
Fremont, Calif.-Verseon, a technology-based pharmaceutical
company employing a computer-driven platform to develop a diverse
drug pipeline, presented preclinical results in its hereditary
angioedema (HAE) program at the 2018 Biotech Showcase in San
Francisco yesterday, January 9. The data show that Verseon's plasma
kallikrein inhibitors are well-suited as oral treatments for this
rare genetic disease.
HAE is characterized by recurring episodes of severe swelling,
which can be life-threatening if they affect the airways. The
disease is caused by a genetic defect which results in reduced
activity of the C1-inhibitor protein, leading to the overactivation
of several serine proteases and subsequent inflammation and edema.
To treat this disease, Verseon is developing oral small-molecule
inhibitors of plasma kallikrein, a serine protease central to the
HAE pathway. The Company's class of drug candidates spans multiple
different chemotypes that show excellent in vitro potency and are
selective against other related serine proteases.
In contrast to currently marketed therapeutics, which rely on
intravenous or subcutaneous injections, Verseon's drug candidates
demonstrate pharmacokinetic exposure suitable for convenient oral
dosing. Dr. David Kita, Verseon's Vice President of R&D, also
presented promising preclinical results that show strong reduction
of swelling after oral administration in a well-established HAE
efficacy model.
"We are very encouraged by these results," said Dr. Kita. "We
started the HAE program only recently, and have already
demonstrated that our oral plasma kallikrein inhibitors have great
potential for the effective management of HAE attacks. The next
milestone this year will be the nomination of our first development
candidate for advancement into clinical trials."
About Verseon's hereditary angioedema program
Verseon is developing small-molecule plasma kallikrein
inhibitors for the treatment of hereditary angioedema. In vitro,
the candidates potently inhibit plasma kallikrein and show
selectivity against a broad range of related serine proteases. Lead
compounds have shown efficacy in a well-established HAE efficacy
model as well as pharmacokinetics suitable for oral dosing.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that pairs a proprietary,
computational drug discovery platform with a comprehensive in-house
chemistry and biology workflow to develop novel therapeutics that
are unlikely to be found using conventional methods. The Company is
applying its platform to a growing drug pipeline and currently has
four active drug programs in the areas of anticoagulation, diabetic
macular edema, hereditary angioedema, and oncology. The
anticoagulation program is scheduled to enter phase I clinical
trials in 2018.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Sebastian Wykeham / Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMGGMRLFGRZM
(END) Dow Jones Newswires
January 10, 2018 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024